keyword
MENU ▼
Read by QxMD icon Read
search

Folfox

keyword
https://www.readbyqxmd.com/read/28917269/triplet-folfoxiri-versus-doublet-folfox-or-folfiri-backbone-chemotherapy-as-first-line-treatment-of-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#1
REVIEW
Rui Pedro Marques, Gonçalo S Duarte, Carmelo Sterrantino, Helena Luna Pais, António Quintela, Ana Paula Martins, João Costa
Uncertainty exists regarding the comparative effectiveness of triplet chemotherapy (FOLFOXIRI) as backbone first-line chemotherapy for metastatic colorectal cancer (mCRC). We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) comparing triplet versus doublet chemotherapy (FOLFOX or FOLFIRI) as first-line therapy in mCRC. Methods and reporting followed PRISMA and SAMPL guidelines. Eight RCTs were included, comprising 1732 patients. In pooled analysis, FOLFOXIRI was associated with improvements in efficacy outcomes, notably with a 25% survival increase (95%CI: 10-37%)...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28915719/genomic-analysis-of-exceptional-responder-to-regorafenib-in-treatment-refractory-metastatic-rectal-cancer-a-case-report-and-review-of-the-literature
#2
Krittiya Korphaisarn, Jonathan M Loree, Van Nguyen, Ryanne Coulson, Vijaykumar Holla, Beate C Litzenburger, Ken Chen, Gordon B Mills, Dipen M Maru, Funda Meric-Bernstan, Kenna R Mills Shaw, Scott Kopetz
We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial response that lasted 27 months. Mutational status was extensively evaluated to identify potential alterations that might play a role as predictive markers for this unusual event. A poorly characterized but nontransforming mutation in Fms-like tyrosine kinase 4 (FLT4) was present in the tumor...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915668/nsc30049-inhibits-chk1-pathway-in-5-fu-resistant-crc-bulk-and-stem-cell-populations
#3
Satya Narayan, Aruna S Jaiswal, Ritika Sharma, Akbar Nawab, Lizette Vila Duckworth, Brian K Law, Maria Zajac-Kaye, Thomas J George, Jay Sharma, Arun K Sharma, Robert A Hromas
The 5-fluorouracil (5-FU) treatment induces DNA damage and stalling of DNA replication forks. These stalled replication forks then collapse to form one sided double-strand breaks, leading to apoptosis. However, colorectal cancer (CRC) stem cells rapidly repair the stalled/collapsed replication forks and overcome treatment effects. Recent evidence suggests a critical role of checkpoint kinase 1 (Chk1) in preventing the replicative stress. Therefore, Chk1 kinase has been a target for developing mono or combination therapeutic agents...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28884391/prognostic-significance-of-surgical-margin-size-after-neoadjuvant-folfox-and-or-folfiri-for-colorectal-liver-metastases
#4
Cynthia L Miller, Martin S Taylor, Motaz Qadan, Vikram Deshpande, Steven Worthington, Robert Smalley, Chey Collura, David P Ryan, Jill N Allen, Lawrence S Blaszkowsky, Jeffrey W Clark, Janet E Murphy, Aparna R Parikh, David Berger, Kenneth K Tanabe, Keith D Lillemoe, Cristina R Ferrone
PURPOSE: Optimal margin size when resecting colorectal liver metastases (CRLM) remains unclear, particularly in the setting of perioperative chemotherapy. We evaluated the prognostic significance of margin size in patients who received neoadjuvant FOLFOX and/or FOLFIRI prior to resection of CRLM. METHODS: Clinicopathologic factors were collected for patients who underwent curative liver resections for CRLM between 4/2004-1/2016 and received neoadjuvant oxaliplatin and/or irinotecan and 5-FU (FOLFOX, FOLFIRI)...
September 7, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28881381/muscle-mass-at-the-time-of-diagnosis-of-nonmetastatic-colon-cancer-and-early-discontinuation-of-chemotherapy-delays-and-dose-reductions-on-adjuvant-folfox-the-c-scans-study
#5
Elizabeth M Cespedes Feliciano, Valerie S Lee, Carla M Prado, Jeffrey A Meyerhardt, Stacey Alexeeff, Candyce H Kroenke, Jingjie Xiao, Adrienne L Castillo, Bette J Caan
BACKGROUND: For many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer. METHODS: The authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients)...
September 7, 2017: Cancer
https://www.readbyqxmd.com/read/28876454/oxaliplatin-induced-increase-in-splenic-volume-irreversible-change-after-adjuvant-folfox
#6
Takuma Iwai, Takeshi Yamada, Michihiro Koizumi, Seiichi Shinji, Yasuyuki Yokoyama, Goro Takahashi, Kohki Takeda, Keisuke Hara, Keiichiro Ohta, Eiji Uchida
BACKGROUND AND OBJECTIVES: Oxaliplatin can cause hepatic sinusoidal obstruction syndrome (SOS). SOS can cause chemotherapy-related adverse effects or morbidity after liver resection. Conventionally, SOS is diagnosed using liver biopsy. Recently, it was reported that increased splenic volume (SV) can be used to detect SOS. In this study, we evaluated the changes in SV during adjuvant chemotherapy. METHODS: We enrolled 103 consecutive patients with stage III and high-risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery...
September 6, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28871992/improved-metastasis-and-disease-free-survival-with-preoperative-sequential-short-course-radiation-therapy-and-folfox-chemotherapy-for-rectal-cancer-compared-with-neoadjuvant-long-course-chemoradiotherapy-results-of-a-matched-pair-analysis
#7
Stephanie Markovina, Fady Youssef, Amit Roy, Sonya Aggarwal, Shariq Khwaja, Todd DeWees, Benjamin Tan, Steven Hunt, Robert J Myerson, Daniel T Chang, Parag J Parikh, Jeffrey R Olsen
PURPOSE: To compare treatment and toxicity outcomes between a phase 2 institutional trial of near total neoadjuvant therapy (nTNT) for locally advanced rectal cancer and a similar historical control cohort treated at Washington University in St. Louis with the current US standard of care, defined as neoadjuvant chemoradiotherapy (NCRT), total mesorectal excision (TME), and adjuvant FOLFOX chemotherapy; to expand the comparison to an additional institution, patients treated with similar NCRT at Stanford University were included...
October 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28870954/first-line-treatment-of-advanced-biliary-ducts-carcinoma-a-randomized-phase-ii-study-evaluating-5-fu-lv-plus-oxaliplatin-folfox-4-versus-5-fu-lv-de-gramont-regimen
#8
RANDOMIZED CONTROLLED TRIAL
Giovanni Schinzari, Ernesto Rossi, Giuseppina Mambella, Antonia Strippoli, Rodolfo Cangiano, Massimiliano Mutignani, Michele Basso, Alessandra Cassano, Carlo Barone
BACKGROUND/AIM: Few clinical trials are available for advanced biliary tract carcinoma (BTC). We conducted this randomized phase II clinical trial to explore efficacy and safety of 5-fluorouracil/leucovorin (5-FU/LV - de Gramont) or the same regimen plus oxaliplatin (Folfox 4) as first-line treatment of advanced BTC. PATIENTS AND METHODS: Primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), response and toxicity. RESULTS: A total of 48 patients were enrolled, 23 in de Gramont arm and 25 in the Folfox arm...
September 2017: Anticancer Research
https://www.readbyqxmd.com/read/28863773/down-regulation-of-mirna-148a-and-mirna-625-3p-in-colorectal-cancer-is-associated-with-tumor-budding
#9
Edita Baltruskeviciene, Diana Schveigert, Vaidotas Stankevicius, Ugnius Mickys, Tadas Zvirblis, Jaroslav Bublevic, Kestutis Suziedelis, Eduardas Aleknavicius
BACKGROUND: MiRNAs are often deregulated in colorectal cancer and might function as tumor suppressors or as oncogenes. They participate in controlling key signaling pathways involved in proliferation, invasion and apoptosis and may serve as prognostic and predictive markers. In this study we aimed to evaluate the role of miRNA-148a and miRNA-625-3p in metastatic colorectal cancer. METHODS: Fifty-four patients with a first-time diagnosed CRC receiving FOLFOX ± Bevacizumab were involved in the study...
September 1, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28851379/prognosis-and-treatment-of-folfox-therapy-related-interstitial-pneumonia-a-plea-for-multimodal-immune-modulating-therapy-in-the-respiratory-insufficient-patient
#10
Annick De Weerdt, Amélie Dendooven, Annemie Snoeckx, Jan Pen, Martin Lammens, Philippe G Jorens
BACKGROUND: The FOLFOX regimen, i.e., folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers. Despite the concomitant improvements in response rate, duration of response and patient survival, reports of serious toxic pulmonary side effects have progressively emerged. CASE PRESENTATION: We describe a patient who was treated with FOLFOX as an adjuvant to a rectosigmoidal resection of a rectosigmoidal carcinoma and who developed respiratory insufficiency requiring mechanical ventilation...
August 29, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28836976/impact-of-nutritional-status-in-the-era-of-folfox-firi-based-chemotherapy
#11
Shunji Okada, Shintaro Yamazaki, Teruo Kaiga, Tomoya Funada, Mitsugu Kochi, Tadatoshi Takayama
BACKGROUND: The nutritional status plays a pivotal role during anticancer therapy. This study analyzed whether nutritional status influences the outcomes in the era of FOLFOX/FIRI therapy. METHODS: The patients were divided into two groups according to whether the nutritional status was well (serum albumin level ≥ 3.8 g/dL or a ≥ 1.0 g/dL increase as compared with the value before chemotherapy) or not before and 2 and 6 months after the start of chemotherapy...
August 24, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28836143/lateral-lymph-node-metastasis-in-a-patient-with-t1-upper-rectal-cancer-treated-by-lateral-lymph-node-dissection-a-case-report-and-brief-literature-review
#12
Hiroyuki Tanishima, Masamichi Kimura, Toshiji Tominaga, Shinji Iwakura, Yoshihiko Hoshida, Tetsuya Horiuchi
BACKGROUND: Lateral lymph node (LLN) metastasis may occur in patients with advanced rectal cancers of which the lower margins are located at or below the peritoneal reflection. However, LLN metastasis from a T1 rectal cancer is rare. Here, we report a case of LLN metastasis from a T1 upper rectal cancer that was successfully treated by sequential LLN dissection. CASE PRESENTATION: A 56-year-old man was referred to our hospital for the treatment of a T1 upper rectal cancer...
August 23, 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28835536/single-cell-functional-and-chemosensitive-profiling-of-combinatorial-colorectal-therapy-in-zebrafish-xenografts
#13
Rita Fior, Vanda Póvoa, Raquel V Mendes, Tânia Carvalho, António Gomes, Nuno Figueiredo, Miguel Godinho Ferreira
Cancer is as unique as the person fighting it. With the exception of a few biomarker-driven therapies, patients go through rounds of trial-and-error approaches to find the best treatment. Using patient-derived cell lines, we show that zebrafish larvae xenotransplants constitute a fast and highly sensitive in vivo model for differential therapy response, with resolution to reveal intratumor functional cancer heterogeneity. We screened international colorectal cancer therapeutic guidelines and determined distinct functional tumor behaviors (proliferation, metastasis, and angiogenesis) and differential sensitivities to standard therapy...
August 23, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28829992/health-related-quality-of-life-results-from-the-prodige-5-accord-17-randomised-trial-of-folfox-versus-fluorouracil-cisplatin-regimen-in-oesophageal-cancer
#14
C Bascoul-Mollevi, S Gourgou, M-P Galais, J-L Raoul, O Bouché, J-Y Douillard, A Adenis, P-L Etienne, B Juzyna, L Bedenne, T Conroy
BACKGROUND: A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens for inoperable non-metastatic oesophageal cancer patients. This secondary analysis aimed to describe the impact of CRT on health-related quality of life (HRQOL), physical functioning, dysphagia, fatigue and pain and to evaluate whether baseline HRQOL domains can predict overall survival. PATIENTS AND METHODS: A total of 267 patients were randomly assigned to receive with 50 Gy of radiotherapy in 25 fractions six cycles of FOLFOX or four cycles of fluorouracil and cisplatin on day 1...
August 19, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28829195/how-and-when-adjuvant-treatment-should-be-intensified-in-stage-iii-colorectal-cancers
#15
Khalil Saleh, Nadine Khalife-Saleh, Hampig Raphael Kourie, Georges Chahine
The adjuvant chemotherapy (FOLFOX) represents the standard of care in stage III colon cancer with some exceptions in old patients. Adjuvant treatment must also be discussed in high-risk stage II colon cancer. However, 40-50% of patients develop disease recurrence after curative R0 surgical resection. The liver was the most common site of recurrence followed by peritoneum. Although adjuvant chemotherapy improved disease-free survival and overall survival, 5-year overall survival remains less than 55% in stage III colon cancer...
August 22, 2017: Future Oncology
https://www.readbyqxmd.com/read/28816286/-prognostic-value-of-chemotherapy-induced-neutropenia-in-metastatic-colon-cancer-patients-undergoing-first-line-chemotherapy-with-folfox
#16
Y Chen, Y R Wang, Y Shi, G H Dai
OBJECTIVE: To evaluate the prognostic value of chemotherapy-induced neutropenia (CIN) in metastatic colon cancer undergoing first-line chemotherapy with FOLFOX. METHODS: Data were collected from a retrospective survey of 158 consecutive metastatic colon cancer patients who had undergone FOLFOX chemotherapy. The clinicopathological characteristics and chemotherapy features of the patients were analyzed as potential prognostic factors. The patients were stratified by the decreased level of CIN to three groups: large decreased level (the number of neutrophil decreased more than 1...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28800321/the-impact-of-chemotherapy-associated-hemoglobin-on-prognosis-of-colorectal-cancer-patients-receiving-adjuvant-chemotherapy
#17
Yi-Sheng Wei, Ya-Guang Zhou, Guo-Ying Wang, Zhi-Hua Liang, Min-Rui Luo, Tian-Ai Yang, Jun Huang
BACKGROUND AND OBJECTIVE: The association of chemotherapy-associated hemoglobin and survival of colorectal cancer (CRC) receiving adjuvant chemotherapy is uncertain. We sought to explore the prognostic value of chemotherapy-associated hemoglobin in CRC receiving adjuvant chemotherapy and the best cut point affecting prognosis. METHODS: Three hundred and twenty stage II and III CRC patients receiving adjuvant FOLFOX chemotherapy from March 2003 to March 2012 were enrolled...
August 1, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28798979/mucosa-associated-invariant-t-cells-infiltrate-hepatic-metastases-in-patients-with-colorectal-carcinoma-but-are-rendered-dysfunctional-within-and-adjacent-to-tumor-microenvironment
#18
Christopher R Shaler, Mauro E Tun-Abraham, Anton I Skaro, Khashayarsha Khazaie, Alexandra J Corbett, Tina Mele, Roberto Hernandez-Alejandro, S M Mansour Haeryfar
Mucosa-associated invariant T (MAIT) cells are innate-like T lymphocytes that are unusually abundant in the human liver, a common site of colorectal carcinoma (CRC) metastasis. However, whether they contribute to immune surveillance against colorectal liver metastasis (CRLM) is essentially unexplored. In addition, whether MAIT cell functions can be impacted by chemotherapy is unclear. These are important questions given MAIT cells' potent immunomodulatory and inflammatory properties. Herein, we examined the frequencies and functions of peripheral blood, healthy liver tissue, tumor-margin and tumor-infiltrating MAIT cells in 21 CRLM patients who received no chemotherapy, FOLFOX, or a combination of FOLFOX and Avastin before they underwent liver resection...
August 10, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28781171/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-liver-metastases-from-colorectal-cancer-foxfire-sirflox-and-foxfire-global-a-combined-analysis-of-three-multicentre-randomised-phase-3-trials
#19
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Guy van Hazel, Ricky A Sharma
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival...
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28771807/combination-adjuvant-chemotherapy-with-targeted-drugs-for-treatment-of-colorectal-cancer-a-network-meta-analysis
#20
Jinghui Wang, Li Luo, Dingxue Wang, Bin Guo, Jun Li, Zhu Yang, Dongxin Tang
BACKGROUND: Colorectal cancer (CRC) is one of the most fatal diseases in the world. The efficacy of present chemotherapy treatments are limited and the addition of targeted drugs have been put into practice. However, the preferred treatments among adjuvant chemotherapies still remain controversial and uncertain. OBJECTIVE: To evaluate the efficacy of different adjuvant chemotherapies combined with or without targeted drugs to determine the optimal treatment for patients with CRC in clinical practice...
August 3, 2017: Journal of Cellular Biochemistry
keyword
keyword
2273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"